When this site last covered orforglipron in a pill without a needle, it was a drug in development. It is now approved in the United States for long-term weight management, alongside reduced calorie intake and increased activity [1].
What makes it different is chemical rather than clinical. Semaglutide and tirzepatide are peptides, which is why they are injected and why the oral semaglutide tablet needs an absorption enhancer and an empty stomach. Orforglipron is a small molecule, so it can be swallowed like an ordinary tablet without those constraints.
On safety at scale, the most substantial evidence so far is a pooled analysis of seven phase 3 trials covering 11,220 participants for up to 104 weeks [2]. Liver enzymes fell on average rather than rose, and categorical elevations were balanced against comparators. Six participants on orforglipron and six on comparators hit the laboratory threshold that triggers a drug-induced liver injury assessment; all six orforglipron cases had an alternative explanation and none met Hy’s Law.
The list of conditions in phase 3 testing is worth reading as a commercial map: obstructive sleep apnea, hypertension, stress urinary incontinence, osteoarthritis pain and peripheral arterial disease. None is approved, and a trial running is not a result. But it shows the strategy this class is pursuing — collecting indications that each unlock a different coverage pathway, which is how a drug excluded from weight-only reimbursement gets paid for anyway.
For a reader the practical question is what a daily tablet changes. Not efficacy, on current evidence: the pooled comparison in the network meta-analysis of nineteen drugs put orforglipron below tirzepatide and alongside injected semaglutide on weight, while ranking it among the highest for stopping because of side effects. What it changes is who will start — needles deter people — and how manufacturing scales, since a small molecule is not limited by peptide synthesis capacity. Whether that translates into lower prices is a separate question, examined in the ecnoglutide trial.